You are here: Industry Insights > COVID-19

News List

APEIRON Biologics Initiates Phase II COVID-19 Trial contractpharma
April 03, 2020
APN01 has potential to block infection of cells by COVID-19 virus and reduce lung injury.
Amgen, Adaptive Biotech Enter COVID-19 Antibody Alliance contractpharma
April 03, 2020
Aims to accelerate the development of a potential antibody against COVID-19 as fast as possible.
Ampio Pharma to Study Ampion in COVID-19 Induced ARDS contractpharma
April 03, 2020
Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug.
Israeli scientists begin animal testing of Covid-19 vaccine prototype pharmaceutical-technology
April 03, 2020
The Israel Institute for Biological Research (IIBR) has made ‘significant’ progress in creating a Covid-19 vaccine prototype and preparations are underway for animal testing, said Prime Minister Benjamin Netanyahu.
ImmunityBio and Microsoft create 3D model to support Covid-19 research pharmaceutical-technology
April 03, 2020
Immunotherapy company ImmunityBio has partnered with Microsoft to leverage the latter’s Azure platform to create a 3D model of Covid-19’s spike protein.
EMA advises malaria drugs use for trials only; FDA records shortage pharmaceutical-technology
April 03, 2020
The European Medicines Agency (EMA) has urged that two malaria drugs, chloroquine and hydroxychloroquine, being tested as potential Covid-19 treatment, must only be used for clinical trials or national emergency use programmes.
Gilead initiates two studies of remdesivir for Covid-19 in UK pharmaceutical-technology
April 03, 2020
Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS pharmaceutical-technology
April 03, 2020
Citius Pharmaceuticals has entered an exclusive six-month option agreement to licence a stem cell therapy from Novellus to treat acute respiratory distress syndrome (ARDS) related to Covid-19 infection.
Ethris, Neurimmune work on inhalable COVID-19 therapy pharmatimes
April 02, 2020
Joining the fight against COVID-19, Ethris GmbH and Neurimmune AG have announced an exclusive partnership to develop an mRNA-based anti-SARS-CoV-2 antibody therapeutic as an inhalable COVID-19 treatment.
NICE publishes second set of rapid COVID-19 guidelines pharmatimes
April 02, 2020
The National Institute for Health and Care Excellence (NICE) has published its second set of rapid guidelines to cover the provision of radiotherapy services and bone marrow transplant during the COVID-19 pandemic.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 437 438 Next page